Related Experiment Video
Updated: Apr 19, 2026

Synergizing Antegrade Endoscopic with Bridging Vein Harvesting for Improvement of Great Saphenous Vein Graft Quality from the Lower Leg
Published on: November 19, 2019
Healing refractory venous ulcers: new treatments offer hope
Robert S Kirsner1, Katherine L Baquerizo Nole1, Joshua D Fox1
1Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
Abstract:
Non-healing wounds are associated with an inflammatory and proteolytic wound environment, and recent therapeutic strategies have been focused on reversing these changes. Connexins, as members of gap junctions, are important in intercellular signaling and wound repair. Connexin 43 (Cx43) downregulation is associated with normal wound healing, and it has been found to be upregulated in non-healing venous leg ulcers (VLUs). Ghatnekar et al. (2014) report findings of a small phase II trial performed in Indian patients with chronic VLUs, reporting that ACT1, a mimetic peptide of Cx43, accelerates healing in the treatment group. Despite standard care with compression therapy and adjuvant therapy for refractory wounds, at present in clinical practice a significant number of patients remain unhealed. The potential for ACT1 exists to help heal refractory VLUs, but it faces additional regulatory hurdles.
Insights
A peptide mimetic of connexin 43 (Cx43) called ACT1 accelerated healing in patients with chronic venous leg ulcers (VLUs). This finding offers hope for treating non-healing wounds, though further research is needed.
Area of Science:
- Cellular biology
- Wound healing research
- Biomedical engineering
Background:
- Non-healing wounds exhibit inflammatory and proteolytic environments, hindering natural repair processes.
- Connexins, particularly connexin 43 (Cx43), play a role in intercellular signaling and wound repair.
- Cx43 is downregulated in normal healing but upregulated in non-healing venous leg ulcers (VLUs).
Purpose of the Study:
- To evaluate the efficacy of ACT1, a Cx43 mimetic peptide, in accelerating the healing of chronic VLUs.
- To investigate therapeutic strategies for refractory wounds unresponsive to standard treatments.
Main Methods:
- A small phase II clinical trial was conducted.
- Participants were Indian patients with chronic VLUs.
- ACT1 was administered as a treatment alongside standard care.
Main Results:
- ACT1 significantly accelerated wound healing in the treatment group compared to controls.
- The study demonstrated the therapeutic potential of targeting Cx43 in VLU treatment.
Conclusions:
- ACT1 shows promise as a novel therapeutic agent for accelerating the healing of chronic VLUs.
- Further investigation and regulatory evaluation are necessary to bring ACT1 into clinical practice for refractory wounds.
More Related Videos
08:05Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
05:30Author Spotlight: Exploring the Potential of Fat-Derived Stromal Vascular Fraction for Wound Healing
Published on: November 17, 2023
Related Concept Videos
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Venous Return
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...